SlideShare a Scribd company logo
1 of 32
Progesterone rise on the day of
hcg administration (ppremature
luteinization) in ivf
Aboubakr Elnashar
Benha university Hospital
Outline
 INTRODUCTION
 DEFINITION
 INCIDENCE
 PATHOGENESIS
 IMPACT ON PREGNANCY OUTCOME
 PREVENTION
 SUMMARY
 RECOMMENDATION
Aboubakr Elnashar
INTRODUCTION
•The introduction of GnRH analogues for pituitary
suppression in ivf significantly decreased the incidence
of premature LH surge
(Smitz et al., 1992).
•However, several researchers have described a
phenomenon reported as PL
(Hofmann et al., 1993; Legro et al., 1993; Ubaldi et al., 1996a; Bosch et al., 2003).
Aboubakr Elnashar
PL:
Rise in serum P on the day of hCG administration.
has aroused interest {some authors reported
decreased implantation& PR}
(Silverberg et al, 1991; Fanchin et al, 1993; Harada et al., 1995)
:Cryopreservation of the embryos& their transfer in a
subsequent cycle
(Silverberg et al., 1991; Legro et al., 1993; Silverberg et al., 1994) or
HCG administration at an earlier time, prior to P
elevation (Harada et al., 1996).
Aboubakr Elnashar
DEFINITION
•Terminology:
PL: Many authors in the past have adopted this term for
P elevation on the day of hCG administration
(Hofmann et al., 1996; Legro et al., 1993;Ubaldi et al., 1996; Bosch et al., 2003).
{Excessive amount of P is produced by granulosa cells
that have started the process of luteinization}.
Aboubakr Elnashar
Use of the term ‘PL’ in the presence of normal
LH levels is not appropriate, at least when GnRHa
is used to inhibit LH surge
(Venetis et al,2007)
Increase in P in the late follicular phase may be
unrelated to any luteinizing process attributable to effects
of follicular cells to LH
(Adonakis et al, 1998)
Aboubakr Elnashar
•P level
(Most studies)
cutoff level 0.8 to 2 ng/mL.
•P/E2 ratio of > 1
(Younis et al, 2001, Ou et al, 2007)
 Ovarian response, rather than the serum P only
DD between the P secretion from dysmature
follicles & physiologic secretion from multiple
healthy mature follicles.
Aboubakr Elnashar
INCIDENCE
•Marked variation: discrepancies in:
Definition
Population characteristics
Treatment protocols.
•Even among studies in which the same
definition (P>0.9 ng/mL) & same protocol (GnRH
a): 12.4%; 52.3%
(Silverberg et al., 1991; Martinez et al., 2004)
Using P only to define: 13% to 71%
Using the definition of P/E2 ratio > 1: 41%
(Younis et al 2001, Ou et al, 2007)
Aboubakr Elnashar
•GnRHa, combined with Gnt: 5-35%
(Edelstein et al, 1990; Silverberg et al, 1991, Fanchin et al, 1993;Givens et al,
1994; Harada et al, 1995;Ubaldi et al, 1995, 1996).
•Flare-up protocol: 85% (P>1.0 ng/ml)
(Sims et al, 1994)
•GnRH antagonist:
(P >1.2 ng/mL): 38.3%
(Bosch et al, 2003)
(P >1.1 ng/mL): 20%
(Ubaldi et al, 1996)
Aboubakr Elnashar
Study Protocol Definition Incidence
Silverberg et al., 1991 GnRHa P >0.9
ng/mL
12.4%
Martinez et al., 2004 GnRHa P >0.9
ng/mL
52.3%
Edelstein et al, 1990; Silverberg et
al, 1991, Fanchin et al, 1993;
Givens et al, 1994; Harada et al,
1995; Ubaldi et al, 1995, 1996
GnRHa P>.8-2
ng/mL.
5-35%
Younis et al 2001; Ou et al, 2007 GnRHa P/E2>1 41%
Ubaldi et al, 1996 GnRH
antagonist
P >1.1
ng/mL
20%
Bosch et al, 2003 GnRH
antagonist
P >1.2
ng/mL
38.3%
Sims et al, 1994 Flare up P>1.0 ng/ml 85%
Aboubakr Elnashar
PATHOGENESIS
Poorly understood
(Melo et al, 2006)
Several hypotheses
I. Elevation of follicular LH levels
 Pituitary desensitization induced by GnRHa is
incomplete:The rising E2: induce increased LH
sufficient to stimulate granulose cells to produce P but
inadequate to trigger ovulation
(Peluso, 1990; Hofmann et al, 1993,Ubaldi et al., 1995)
 long GnRHa protocol can prevent premature LH
elevation in 95–98% (Ron , 1990; Penzias et al, 1992)
 Increased LH is not the only pathogenic factor in PL
Aboubakr Elnashar
II. Serum accumulation of HCG from HMG
(Copperman et al, 1995)
hCG is higher in women who experienced a serum P rise,
during GnRHa HMG protocol, despite pituitary suppression with
GnRHa
Use of rFSH (with negligible intrinsic LH bioactivity) should not
provoke PL
(Peluso, 1990).
Serum P rise was similar (13.4%) with the use of HMG or rFSH
(Ubaldi et al, 1996).
HCG content of HMG is not the only cause of serum P rise.
Aboubakr Elnashar
III. Increased LH receptor sensitivity of the granulosa
cells to FSH.
{ higher cumulative exposure to E2, in conjunction with
FSH}
(Peluso, 1990; Ubaldi et al, 1996; Filicori et al., 2002; Bosch et al., 2003; Glamoclija et al.,
2005).
Aboubakr Elnashar
IV. Poor ovarian response with increased LH
sensitivity
PL (defined by the P/E2) was more prevalent in poor
ovarian responders in long GnRHa cycles with rFSH
stimulation.
(Younis et al 2001; Ou et al, 2007)
PL is not necessarily an LH dependent event
PL is related to an adversely affected cumulus–oocyte
complex.
Increase in P in the late follicular phase is unrelated to
any luteinizing process attributable to effects of follicular
cells to LH
(Adonakis et al, 1998)
Aboubakr Elnashar
IMPACT ON IVF OUTCOME
•Controversial
•No effect on PR
(Howles et al., 1988; Mahadevan et al., 1988; Ben-Nun et al., 1990; Hassiakos et al.,
1990; Antoine et al., 1992; Hoffman et al. 1993, 1996; Check et al., 1994; Givens et al.,
1994; Bustillo et al., 1995; Levy et al., 1995; Ubaldi et al., 1995; Abuzeid and Sasy,
1996; Huang et al., 1996; Miller et al., 1996; Moffit et al., 1997; Doldi et al., 1999;
Lindheim et al., 1999; Urman et al., 1999; Martinez et al., 2004) 20 studies
Aboubakr Elnashar
•Deleterious effect
PR has been inversely related to serum P levels on the
day of HCG administration
(Hamori et al., 1987; Edelstein et al., 1990; Schoolcraft et al., 1991; Silverberg et al., 1991;
Kagawa et al., 1992; Mio et al., 1992; Fanchin et al., 1993; Check et al., 1994; Givens et al.,
1994; Mio and Terakawa, 1995; Harada et al., 1995; Shulman et al., 1996; Fanchin et
al.,1997; Bosch et al., 2003; Ozcakir et al., 2004 Ou et al, 2007; ) 16 studies
Aboubakr Elnashar
•Ovarian:
Adverse effects on oocyte maturation, fertilization or
early cleavage
(Fanchimont et al., 1989; Schoolcraft et al., 1991; Silverberg et al., 1991; Fanchin et al.,
1993, 1997a).
On the other hand, poorer embryo quality was not
found
(Legro et al., 1993; Hofmann et al., 1993, 1996; Check et al., 1994; Silverberg et al.,
1994;Bustillo et al., 1995; Yovel et al., 1995; Fanchin et al., 1996).
Aboubakr Elnashar
•Endometrium:
Adverse effects on implantation& subsequent embryo
development
(Garcia et al., 1984; Forman et al., 1989; Sharma et al., 1990; Silverberg et al., 1991; Mio et
al., 1992; Burns et al., 1994; Borman et al., 2004).
Abnormally accelerated endometrial maturation:
impaired endometrial receptivity
(Forman et al. 1989, Sharma et al. 1990; Silverberg et al. 1991)
P supplementation for luteal phase support started on
the day of HCG: No negative impact on PR
(Howles et al., 1988; Mahadevan et al., 1988; Ben-Nun et al., 1990; Hassiakos et al., 1990).
Aboubakr Elnashar
Is P elevation on the day of HCG administration
associated with the probability of pregnancy in IVF?
A systematic review and meta-analysis
C.A.Venetis, E.M.Kolibianakis, E.Papanikolaou, J.Bontis,
P.Devroey and B.C.Tarlatzis1, Hum Rep, 2007
Aim:
To evaluate whether P elevation on the day of
hCG administration is associated with the
probability of pregnancy.
Aboubakr Elnashar
Material & Methods:
Eligible studies were considered those in which patients
did not participate more than once.
A literature search in MEDLINE, EMBASE& CENTRAL
identified 12 eligible studies, 10 of which were
retrospective.
Aboubakr Elnashar
Results
The majority (n=10) of these studies did not detect a statistically significant
association between P elevation& the probability of pregnancy.
Metaanalysis was performed only for the studies (n=5) that provided data on
clinical pregnancy per patient reaching hCG administration for final oocyte
maturation.
No statistically significant association between P elevation& the probability
of clinical pregnancy.
Aboubakr Elnashar
Conclusion:
Best available evidence does not support an
association between P elevation on the day of hCG
administration& the probability of clinical
pregnancy in women undergoing ovarian
stimulation with GnRH analogues& Gnt for IVF.
Aboubakr Elnashar
PREVENTION
I. Low-dose hCG alone in the late COH stages:
(Filicori et al, 2005)
rFSH/hMG followed by low-dose hCG (200 IU/d) alone :
Reduced rFSH/hMG consumption
ICSI outcome was comparable to traditional COH regimens
Stimulated follicle growth and maturation independent of FSH
administration
Reduced number of small preovulatory follicles
More estrogenic intrafollicular environment.
No PL
Aboubakr Elnashar
II. Flexible antagonist protocol
(Lainas et al, 2005)
GnRH antagonist was initiated according to at least
one of the following
(i) at least one follicle >14 mm
(ii)E2 >600 pg/ml
(iii)LH levels >10 IU/l.
 Antagonist initiation earlier than on stimulation D6
 Higher PR
 Prevention of premature LH surges
 Absence of PL (normal P levels on HCG day).
Aboubakr Elnashar
III. Mifepristone
(Escudero et al, 2005)
:long protocol with GnRHa
Mifepristone: 40 mg daily, 50 mg progesterone were
administered IM at the time of hCG administration
{counteract residual antiprogestogenic activity of
mifepristone}.
Mifepristone is effective for the prevention of
premature LH surges and/or PL
Aboubakr Elnashar
VI. hCG injection when serum P >1.0 ng/mL
("rescued" subtle P rise).
(Harada et al, 1996)
•Serum P was determined daily or/ 12 h from D7
until the administration of hCG.
improves embryo quality
implantation rate was significantly higher
Aboubakr Elnashar
V. Aspiration of a single leading follicle
(Barash et al, 1990)
•Single leading follicle developed, whereas
the other follicles were 6 mm smaller
Efficient method to avoid premature LH
surge enabling other follicles to develop up
to the preovulatory stage.
Aboubakr Elnashar
SUMMARY
PL
•Subtle rise of P on the day of hCG administration (0.8 to
2 ng/Ml)
•There is a marked variation in the incidence (13% to
71%), due to discrepancies in
Definition
Population characteristics
Treatment protocols.
Aboubakr Elnashar
•Several hypotheses:
Elevation of follicular LH levels
Serum accumulation of HCG from HMG
Increased LH receptor sensitivity of the granulosa cells to
FSH
Poor ovarian response with increased LH sensitivity
Aboubakr Elnashar
•Impact on IVF outcome is controversial. A recent
systematic review& meta-analysis affirmed that no effect
•For prevention:
Use of Low-dose hCG alone in the late COH stages
Flexible antagonist protocol
Use of mifepristone
hCG administration when the levels of P>1.0 ng/mL.
Aspiration of a single leading follicle
Aboubakr Elnashar
RECOMMENDATION
A well-designed prospective studies
are required to answer the question:
What is the role of P elevation on IVF
outcome?
Aboubakr Elnashar
Thanks
Aboubakr Elnashar

More Related Content

What's hot

Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharAboubakr Elnashar
 
Endometrial Scratching
Endometrial ScratchingEndometrial Scratching
Endometrial ScratchingAli Smith
 
Progesterone rise and IVF success
Progesterone rise and IVF successProgesterone rise and IVF success
Progesterone rise and IVF successSandro Esteves
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiBharati Dhorepatil
 
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Lifecare Centre
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilBharati Dhorepatil
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationSandro Esteves
 
Use of LH in IVF and IUI
Use of LH in IVF and IUIUse of LH in IVF and IUI
Use of LH in IVF and IUISandro Esteves
 
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Anu Test Tube Baby Centre
 
Controlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFControlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFAboubakr Elnashar
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIDR SHASHWAT JANI
 
Luteal phase support in ART Cases Dr Sharda Jain
Luteal phase  support in ART Cases Dr Sharda Jain Luteal phase  support in ART Cases Dr Sharda Jain
Luteal phase support in ART Cases Dr Sharda Jain Lifecare Centre
 
Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor RespondersSandro Esteves
 
Ivf stimulation protocols by Dr. Mahalakshmi Saravanan
Ivf stimulation protocols by Dr. Mahalakshmi SaravananIvf stimulation protocols by Dr. Mahalakshmi Saravanan
Ivf stimulation protocols by Dr. Mahalakshmi SaravananMorris Jawahar
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiBharati Dhorepatil
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Sandro Esteves
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failureAhmad Saber
 
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ART
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ARTUNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ART
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ARTNARENDRA MALHOTRA
 

What's hot (20)

Monitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr ElnasharMonitoring ART cycle Aboubakr Elnashar
Monitoring ART cycle Aboubakr Elnashar
 
Endometrial Scratching
Endometrial ScratchingEndometrial Scratching
Endometrial Scratching
 
Fet endometrial preparation
Fet endometrial preparationFet endometrial preparation
Fet endometrial preparation
 
Progesterone rise and IVF success
Progesterone rise and IVF successProgesterone rise and IVF success
Progesterone rise and IVF success
 
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil BharatiOvulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
Ovulation Stimulation Protocols for IUI - Dr Dhorepatil Bharati
 
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
Fresh Vs Frozen Embryo Transfer What’s The Current Practice? : Dr Sharda Jain
 
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati DhorepatilPCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
PCOS - Ovulation Induction 1 - Dr Bharati Dhorepatil
 
Role of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian StimulationRole of LH in Controlled Ovarian Stimulation
Role of LH in Controlled Ovarian Stimulation
 
Unexplained infertility
Unexplained infertilityUnexplained infertility
Unexplained infertility
 
Use of LH in IVF and IUI
Use of LH in IVF and IUIUse of LH in IVF and IUI
Use of LH in IVF and IUI
 
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
Optimal protocols for Ovulation induction (Assisted Reproductive technologies)
 
Controlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVFControlled ovarian stimulation in IVF
Controlled ovarian stimulation in IVF
 
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANIEVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
EVIDENCE BASED PRACTICAL TIPS FOR LUTEAL PHASE SUPPORT BY DR SHASHWAT JANI
 
Luteal phase support in ART Cases Dr Sharda Jain
Luteal phase  support in ART Cases Dr Sharda Jain Luteal phase  support in ART Cases Dr Sharda Jain
Luteal phase support in ART Cases Dr Sharda Jain
 
Management of Poor Responders
Management of Poor RespondersManagement of Poor Responders
Management of Poor Responders
 
Ivf stimulation protocols by Dr. Mahalakshmi Saravanan
Ivf stimulation protocols by Dr. Mahalakshmi SaravananIvf stimulation protocols by Dr. Mahalakshmi Saravanan
Ivf stimulation protocols by Dr. Mahalakshmi Saravanan
 
Unexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil BharatiUnexplained Infertility - By Dr Dhorepatil Bharati
Unexplained Infertility - By Dr Dhorepatil Bharati
 
Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?Number of oocytes and progesterone levels in IVF: Do they matter?
Number of oocytes and progesterone levels in IVF: Do they matter?
 
Repeated Implantation failure
Repeated Implantation failureRepeated Implantation failure
Repeated Implantation failure
 
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ART
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ARTUNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ART
UNDERSTANDING DOWN REGULATION GnRH Agonists and Antagonists In ART
 

Viewers also liked

Contraception elligability criteria WHO: Aboubakr Elnashar
Contraception elligability criteria WHO: Aboubakr ElnasharContraception elligability criteria WHO: Aboubakr Elnashar
Contraception elligability criteria WHO: Aboubakr ElnasharAboubakr Elnashar
 
Improving Success by Tailoring Ovarian Stimulation
Improving Success by Tailoring Ovarian StimulationImproving Success by Tailoring Ovarian Stimulation
Improving Success by Tailoring Ovarian StimulationSandro Esteves
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Sandro Esteves
 
Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancyAboubakr Elnashar
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESfatihkaraosmanoglu.net
 
Novel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase supportNovel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase supportSandro Esteves
 
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by IndividualizationMaximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by IndividualizationSandro Esteves
 
Embryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharEmbryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharAboubakr Elnashar
 
In vitro fertilization embryo transfer
In vitro fertilization embryo transferIn vitro fertilization embryo transfer
In vitro fertilization embryo transferNiyamat Panjesha
 
State of the Word 2011
State of the Word 2011State of the Word 2011
State of the Word 2011photomatt
 

Viewers also liked (15)

Contraception elligability criteria WHO: Aboubakr Elnashar
Contraception elligability criteria WHO: Aboubakr ElnasharContraception elligability criteria WHO: Aboubakr Elnashar
Contraception elligability criteria WHO: Aboubakr Elnashar
 
Improving Success by Tailoring Ovarian Stimulation
Improving Success by Tailoring Ovarian StimulationImproving Success by Tailoring Ovarian Stimulation
Improving Success by Tailoring Ovarian Stimulation
 
Induction of labour2013
Induction of labour2013Induction of labour2013
Induction of labour2013
 
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
Embryo Transfer Technologies and Luteal Phase Support to Maximize Pregnancy R...
 
Embryo transfer
Embryo transferEmbryo transfer
Embryo transfer
 
Obstetric cholestasis
Obstetric cholestasisObstetric cholestasis
Obstetric cholestasis
 
Thrombocytopenia during pregnancy
Thrombocytopenia during pregnancyThrombocytopenia during pregnancy
Thrombocytopenia during pregnancy
 
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLESENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
ENDOMETRIAL PREPARATION IN FROZEN EMBRYO TRANSFER CYCLES
 
Novel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase supportNovel treatments to trigger final follicular maturation and luteal phase support
Novel treatments to trigger final follicular maturation and luteal phase support
 
Embryo transfer
Embryo transferEmbryo transfer
Embryo transfer
 
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by IndividualizationMaximizing Outcomes in Assisted Reproductive Technology by Individualization
Maximizing Outcomes in Assisted Reproductive Technology by Individualization
 
Embryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr ElnasharEmbryo transfer: Aboubakr Elnashar
Embryo transfer: Aboubakr Elnashar
 
Embryo Transfer
Embryo TransferEmbryo Transfer
Embryo Transfer
 
In vitro fertilization embryo transfer
In vitro fertilization embryo transferIn vitro fertilization embryo transfer
In vitro fertilization embryo transfer
 
State of the Word 2011
State of the Word 2011State of the Word 2011
State of the Word 2011
 

Similar to Progesterone rise on the day of hcg administration (ppremature luteinization) in ivf

Progesterone elevation on the day of HCG administration in ivf
Progesterone elevation on the day of HCG administration in ivfProgesterone elevation on the day of HCG administration in ivf
Progesterone elevation on the day of HCG administration in ivf Aboubakr Elnashar
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTSandro Esteves
 
L3 alviggi lh bucarest 2013
L3 alviggi lh bucarest 2013L3 alviggi lh bucarest 2013
L3 alviggi lh bucarest 2013t7260678
 
L3 alviggi lh bucarest 2013 (1)
L3 alviggi lh bucarest 2013 (1)L3 alviggi lh bucarest 2013 (1)
L3 alviggi lh bucarest 2013 (1)t7260678
 
Ovarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationOvarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationmohamedbehery2
 
Gonadotropins.pptx
Gonadotropins.pptxGonadotropins.pptx
Gonadotropins.pptxRaju Nair
 
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi AjayiFinal Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayiabayomi ajayi
 
Evidence Based Approach to Luteal Phase Support in IVF Cycles
Evidence Based Approach to Luteal Phase Support in IVF CyclesEvidence Based Approach to Luteal Phase Support in IVF Cycles
Evidence Based Approach to Luteal Phase Support in IVF CyclesDr. Snehal Dhobale Kohale
 
GnRH antagonist in Ovarian stimulation for IVF/ET, Prof. Usama M.Fouda
GnRH antagonist in Ovarian stimulation for   IVF/ET, Prof. Usama M.Fouda GnRH antagonist in Ovarian stimulation for   IVF/ET, Prof. Usama M.Fouda
GnRH antagonist in Ovarian stimulation for IVF/ET, Prof. Usama M.Fouda umfrfouda
 
Lh in assisted reproduction by DR G A RAMARAJU
Lh in assisted reproduction by DR G A RAMARAJULh in assisted reproduction by DR G A RAMARAJU
Lh in assisted reproduction by DR G A RAMARAJUG A RAMA Raju
 
Monitoring of IVF Cycle - Dr Dhorepatil Bharati
Monitoring of IVF Cycle - Dr Dhorepatil BharatiMonitoring of IVF Cycle - Dr Dhorepatil Bharati
Monitoring of IVF Cycle - Dr Dhorepatil BharatiBharati Dhorepatil
 
Obesity, SLE, Thyroid disease and ICSI
Obesity, SLE, Thyroid  disease   and ICSIObesity, SLE, Thyroid  disease   and ICSI
Obesity, SLE, Thyroid disease and ICSIAboubakr Elnashar
 
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVFCURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVFAboubakr Elnashar
 
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...Candido Tomás
 
Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Hesham Al-Inany
 

Similar to Progesterone rise on the day of hcg administration (ppremature luteinization) in ivf (20)

Progesterone elevation on the day of HCG administration in ivf
Progesterone elevation on the day of HCG administration in ivfProgesterone elevation on the day of HCG administration in ivf
Progesterone elevation on the day of HCG administration in ivf
 
Luteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ARTLuteal Phase Support: Key Variables to Achieve Success in ART
Luteal Phase Support: Key Variables to Achieve Success in ART
 
Luteal Phase Support In IVF
Luteal Phase Support In IVFLuteal Phase Support In IVF
Luteal Phase Support In IVF
 
L3 alviggi lh bucarest 2013
L3 alviggi lh bucarest 2013L3 alviggi lh bucarest 2013
L3 alviggi lh bucarest 2013
 
L3 alviggi lh bucarest 2013 (1)
L3 alviggi lh bucarest 2013 (1)L3 alviggi lh bucarest 2013 (1)
L3 alviggi lh bucarest 2013 (1)
 
Ovarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulationOvarian waves and random ovarian stimulation
Ovarian waves and random ovarian stimulation
 
Gonadotropins.pptx
Gonadotropins.pptxGonadotropins.pptx
Gonadotropins.pptx
 
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi AjayiFinal Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
Final Oocyte Maturation: HCG VS GNRH Agonist by Dr. Abayomi Ajayi
 
Evidence Based Approach to Luteal Phase Support in IVF Cycles
Evidence Based Approach to Luteal Phase Support in IVF CyclesEvidence Based Approach to Luteal Phase Support in IVF Cycles
Evidence Based Approach to Luteal Phase Support in IVF Cycles
 
GnRH Agonist Versus GnRH Antagonist
GnRH Agonist Versus GnRH AntagonistGnRH Agonist Versus GnRH Antagonist
GnRH Agonist Versus GnRH Antagonist
 
GnRH antagonist in Ovarian stimulation for IVF/ET, Prof. Usama M.Fouda
GnRH antagonist in Ovarian stimulation for   IVF/ET, Prof. Usama M.Fouda GnRH antagonist in Ovarian stimulation for   IVF/ET, Prof. Usama M.Fouda
GnRH antagonist in Ovarian stimulation for IVF/ET, Prof. Usama M.Fouda
 
Ohss
OhssOhss
Ohss
 
Lh in assisted reproduction by DR G A RAMARAJU
Lh in assisted reproduction by DR G A RAMARAJULh in assisted reproduction by DR G A RAMARAJU
Lh in assisted reproduction by DR G A RAMARAJU
 
Monitoring of IVF Cycle - Dr Dhorepatil Bharati
Monitoring of IVF Cycle - Dr Dhorepatil BharatiMonitoring of IVF Cycle - Dr Dhorepatil Bharati
Monitoring of IVF Cycle - Dr Dhorepatil Bharati
 
Obesity, SLE, Thyroid disease and ICSI
Obesity, SLE, Thyroid  disease   and ICSIObesity, SLE, Thyroid  disease   and ICSI
Obesity, SLE, Thyroid disease and ICSI
 
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVFCURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
CURRENT EVIDENCE ON MEDICAL ADD-ONS IN IVF
 
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
To pill or not to pill in GnRa-antagonist protocols Candido Tomás, Ovumia 030...
 
Gn rh
Gn rhGn rh
Gn rh
 
Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018Poor response in IVF : How to manage : 2018
Poor response in IVF : How to manage : 2018
 
Ovarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohssOvarian hyper stimulation syndrome ohss
Ovarian hyper stimulation syndrome ohss
 

More from Aboubakr Elnashar

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTAboubakr Elnashar
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertilityAboubakr Elnashar
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Aboubakr Elnashar
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversyAboubakr Elnashar
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gynAboubakr Elnashar
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineAboubakr Elnashar
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationAboubakr Elnashar
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA Aboubakr Elnashar
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021 Aboubakr Elnashar
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown locationAboubakr Elnashar
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021Aboubakr Elnashar
 

More from Aboubakr Elnashar (20)

WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGISTWHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
WHAT IS NEW IN ESHRE 2022 AND FIGO 2022 FOR GENERAL GYNAECOLOGIST
 
hepatitis B.pdf
hepatitis B.pdfhepatitis B.pdf
hepatitis B.pdf
 
hepatitis c2022.pdf
hepatitis c2022.pdfhepatitis c2022.pdf
hepatitis c2022.pdf
 
Adenomyosis associated infertility
Adenomyosis associated  infertilityAdenomyosis associated  infertility
Adenomyosis associated infertility
 
Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022Endometriosis associated infertility: ESHRE2022
Endometriosis associated infertility: ESHRE2022
 
Adenxal mass guidelines2020
Adenxal mass guidelines2020Adenxal mass guidelines2020
Adenxal mass guidelines2020
 
Aesthetic gynecology controversy
Aesthetic gynecology controversyAesthetic gynecology controversy
Aesthetic gynecology controversy
 
Hormonal assay in clinical gyn
Hormonal assay in clinical gynHormonal assay in clinical gyn
Hormonal assay in clinical gyn
 
FIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVFFIRST TRIMESTER ANC OF IVF
FIRST TRIMESTER ANC OF IVF
 
Unnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicineUnnecessary investigations in reproductive medicine
Unnecessary investigations in reproductive medicine
 
Infertility prevention
Infertility prevention Infertility prevention
Infertility prevention
 
Individualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulationIndividualisation of controlled ovarian stimulation
Individualisation of controlled ovarian stimulation
 
Female infertility
Female infertility Female infertility
Female infertility
 
Maternal near miss
Maternal near missMaternal near miss
Maternal near miss
 
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
THE MANAGEMENT OF SEVERE PET/ECLAMPSIA
 
cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021  cesarean birth: procedural aspects: NICE2021
cesarean birth: procedural aspects: NICE2021
 
CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT  CAESAREAN SCAR DEFECT
CAESAREAN SCAR DEFECT
 
Management of pregnancy of unknown location
Management of pregnancy of unknown locationManagement of pregnancy of unknown location
Management of pregnancy of unknown location
 
Aerobic Vaginitis
Aerobic Vaginitis Aerobic Vaginitis
Aerobic Vaginitis
 
COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021COVID 19 infection and pregnancy RCOG2021
COVID 19 infection and pregnancy RCOG2021
 

Recently uploaded

VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsMedicoseAcademics
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️saminamagar
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxDr. Dheeraj Kumar
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxDr. Dheeraj Kumar
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?bkling
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdfDolisha Warbi
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAAjennyeacort
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxbkling
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxDr. Dheeraj Kumar
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...saminamagar
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdfDolisha Warbi
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 

Recently uploaded (20)

VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
Hematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes FunctionsHematology and Immunology - Leukocytes Functions
Hematology and Immunology - Leukocytes Functions
 
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️call girls in green park  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
call girls in green park DELHI 🔝 >༒9540349809 🔝 genuine Escort Service 🔝✔️✔️
 
Culture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptxCulture and Health Disorders Social change.pptx
Culture and Health Disorders Social change.pptx
 
Measurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptxMeasurement of Radiation and Dosimetric Procedure.pptx
Measurement of Radiation and Dosimetric Procedure.pptx
 
Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?Let's Talk About It: To Disclose or Not to Disclose?
Let's Talk About It: To Disclose or Not to Disclose?
 
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
PNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdfPNEUMOTHORAX   AND  ITS  MANAGEMENTS.pdf
PNEUMOTHORAX AND ITS MANAGEMENTS.pdf
 
Epilepsy
EpilepsyEpilepsy
Epilepsy
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA97111 47426 Call Girls In Delhi MUNIRKAA
97111 47426 Call Girls In Delhi MUNIRKAA
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Report Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptxReport Back from SGO: What’s New in Uterine Cancer?.pptx
Report Back from SGO: What’s New in Uterine Cancer?.pptx
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Radiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptxRadiation Dosimetry Parameters and Isodose Curves.pptx
Radiation Dosimetry Parameters and Isodose Curves.pptx
 
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...call girls in Connaught Place  DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
call girls in Connaught Place DELHI 🔝 >༒9540349809 🔝 genuine Escort Service ...
 
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
PULMONARY EDEMA AND  ITS  MANAGEMENT.pdfPULMONARY EDEMA AND  ITS  MANAGEMENT.pdf
PULMONARY EDEMA AND ITS MANAGEMENT.pdf
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 

Progesterone rise on the day of hcg administration (ppremature luteinization) in ivf

  • 1. Progesterone rise on the day of hcg administration (ppremature luteinization) in ivf Aboubakr Elnashar Benha university Hospital
  • 2. Outline  INTRODUCTION  DEFINITION  INCIDENCE  PATHOGENESIS  IMPACT ON PREGNANCY OUTCOME  PREVENTION  SUMMARY  RECOMMENDATION Aboubakr Elnashar
  • 3. INTRODUCTION •The introduction of GnRH analogues for pituitary suppression in ivf significantly decreased the incidence of premature LH surge (Smitz et al., 1992). •However, several researchers have described a phenomenon reported as PL (Hofmann et al., 1993; Legro et al., 1993; Ubaldi et al., 1996a; Bosch et al., 2003). Aboubakr Elnashar
  • 4. PL: Rise in serum P on the day of hCG administration. has aroused interest {some authors reported decreased implantation& PR} (Silverberg et al, 1991; Fanchin et al, 1993; Harada et al., 1995) :Cryopreservation of the embryos& their transfer in a subsequent cycle (Silverberg et al., 1991; Legro et al., 1993; Silverberg et al., 1994) or HCG administration at an earlier time, prior to P elevation (Harada et al., 1996). Aboubakr Elnashar
  • 5. DEFINITION •Terminology: PL: Many authors in the past have adopted this term for P elevation on the day of hCG administration (Hofmann et al., 1996; Legro et al., 1993;Ubaldi et al., 1996; Bosch et al., 2003). {Excessive amount of P is produced by granulosa cells that have started the process of luteinization}. Aboubakr Elnashar
  • 6. Use of the term ‘PL’ in the presence of normal LH levels is not appropriate, at least when GnRHa is used to inhibit LH surge (Venetis et al,2007) Increase in P in the late follicular phase may be unrelated to any luteinizing process attributable to effects of follicular cells to LH (Adonakis et al, 1998) Aboubakr Elnashar
  • 7. •P level (Most studies) cutoff level 0.8 to 2 ng/mL. •P/E2 ratio of > 1 (Younis et al, 2001, Ou et al, 2007)  Ovarian response, rather than the serum P only DD between the P secretion from dysmature follicles & physiologic secretion from multiple healthy mature follicles. Aboubakr Elnashar
  • 8. INCIDENCE •Marked variation: discrepancies in: Definition Population characteristics Treatment protocols. •Even among studies in which the same definition (P>0.9 ng/mL) & same protocol (GnRH a): 12.4%; 52.3% (Silverberg et al., 1991; Martinez et al., 2004) Using P only to define: 13% to 71% Using the definition of P/E2 ratio > 1: 41% (Younis et al 2001, Ou et al, 2007) Aboubakr Elnashar
  • 9. •GnRHa, combined with Gnt: 5-35% (Edelstein et al, 1990; Silverberg et al, 1991, Fanchin et al, 1993;Givens et al, 1994; Harada et al, 1995;Ubaldi et al, 1995, 1996). •Flare-up protocol: 85% (P>1.0 ng/ml) (Sims et al, 1994) •GnRH antagonist: (P >1.2 ng/mL): 38.3% (Bosch et al, 2003) (P >1.1 ng/mL): 20% (Ubaldi et al, 1996) Aboubakr Elnashar
  • 10. Study Protocol Definition Incidence Silverberg et al., 1991 GnRHa P >0.9 ng/mL 12.4% Martinez et al., 2004 GnRHa P >0.9 ng/mL 52.3% Edelstein et al, 1990; Silverberg et al, 1991, Fanchin et al, 1993; Givens et al, 1994; Harada et al, 1995; Ubaldi et al, 1995, 1996 GnRHa P>.8-2 ng/mL. 5-35% Younis et al 2001; Ou et al, 2007 GnRHa P/E2>1 41% Ubaldi et al, 1996 GnRH antagonist P >1.1 ng/mL 20% Bosch et al, 2003 GnRH antagonist P >1.2 ng/mL 38.3% Sims et al, 1994 Flare up P>1.0 ng/ml 85% Aboubakr Elnashar
  • 11. PATHOGENESIS Poorly understood (Melo et al, 2006) Several hypotheses I. Elevation of follicular LH levels  Pituitary desensitization induced by GnRHa is incomplete:The rising E2: induce increased LH sufficient to stimulate granulose cells to produce P but inadequate to trigger ovulation (Peluso, 1990; Hofmann et al, 1993,Ubaldi et al., 1995)  long GnRHa protocol can prevent premature LH elevation in 95–98% (Ron , 1990; Penzias et al, 1992)  Increased LH is not the only pathogenic factor in PL Aboubakr Elnashar
  • 12. II. Serum accumulation of HCG from HMG (Copperman et al, 1995) hCG is higher in women who experienced a serum P rise, during GnRHa HMG protocol, despite pituitary suppression with GnRHa Use of rFSH (with negligible intrinsic LH bioactivity) should not provoke PL (Peluso, 1990). Serum P rise was similar (13.4%) with the use of HMG or rFSH (Ubaldi et al, 1996). HCG content of HMG is not the only cause of serum P rise. Aboubakr Elnashar
  • 13. III. Increased LH receptor sensitivity of the granulosa cells to FSH. { higher cumulative exposure to E2, in conjunction with FSH} (Peluso, 1990; Ubaldi et al, 1996; Filicori et al., 2002; Bosch et al., 2003; Glamoclija et al., 2005). Aboubakr Elnashar
  • 14. IV. Poor ovarian response with increased LH sensitivity PL (defined by the P/E2) was more prevalent in poor ovarian responders in long GnRHa cycles with rFSH stimulation. (Younis et al 2001; Ou et al, 2007) PL is not necessarily an LH dependent event PL is related to an adversely affected cumulus–oocyte complex. Increase in P in the late follicular phase is unrelated to any luteinizing process attributable to effects of follicular cells to LH (Adonakis et al, 1998) Aboubakr Elnashar
  • 15. IMPACT ON IVF OUTCOME •Controversial •No effect on PR (Howles et al., 1988; Mahadevan et al., 1988; Ben-Nun et al., 1990; Hassiakos et al., 1990; Antoine et al., 1992; Hoffman et al. 1993, 1996; Check et al., 1994; Givens et al., 1994; Bustillo et al., 1995; Levy et al., 1995; Ubaldi et al., 1995; Abuzeid and Sasy, 1996; Huang et al., 1996; Miller et al., 1996; Moffit et al., 1997; Doldi et al., 1999; Lindheim et al., 1999; Urman et al., 1999; Martinez et al., 2004) 20 studies Aboubakr Elnashar
  • 16. •Deleterious effect PR has been inversely related to serum P levels on the day of HCG administration (Hamori et al., 1987; Edelstein et al., 1990; Schoolcraft et al., 1991; Silverberg et al., 1991; Kagawa et al., 1992; Mio et al., 1992; Fanchin et al., 1993; Check et al., 1994; Givens et al., 1994; Mio and Terakawa, 1995; Harada et al., 1995; Shulman et al., 1996; Fanchin et al.,1997; Bosch et al., 2003; Ozcakir et al., 2004 Ou et al, 2007; ) 16 studies Aboubakr Elnashar
  • 17. •Ovarian: Adverse effects on oocyte maturation, fertilization or early cleavage (Fanchimont et al., 1989; Schoolcraft et al., 1991; Silverberg et al., 1991; Fanchin et al., 1993, 1997a). On the other hand, poorer embryo quality was not found (Legro et al., 1993; Hofmann et al., 1993, 1996; Check et al., 1994; Silverberg et al., 1994;Bustillo et al., 1995; Yovel et al., 1995; Fanchin et al., 1996). Aboubakr Elnashar
  • 18. •Endometrium: Adverse effects on implantation& subsequent embryo development (Garcia et al., 1984; Forman et al., 1989; Sharma et al., 1990; Silverberg et al., 1991; Mio et al., 1992; Burns et al., 1994; Borman et al., 2004). Abnormally accelerated endometrial maturation: impaired endometrial receptivity (Forman et al. 1989, Sharma et al. 1990; Silverberg et al. 1991) P supplementation for luteal phase support started on the day of HCG: No negative impact on PR (Howles et al., 1988; Mahadevan et al., 1988; Ben-Nun et al., 1990; Hassiakos et al., 1990). Aboubakr Elnashar
  • 19. Is P elevation on the day of HCG administration associated with the probability of pregnancy in IVF? A systematic review and meta-analysis C.A.Venetis, E.M.Kolibianakis, E.Papanikolaou, J.Bontis, P.Devroey and B.C.Tarlatzis1, Hum Rep, 2007 Aim: To evaluate whether P elevation on the day of hCG administration is associated with the probability of pregnancy. Aboubakr Elnashar
  • 20. Material & Methods: Eligible studies were considered those in which patients did not participate more than once. A literature search in MEDLINE, EMBASE& CENTRAL identified 12 eligible studies, 10 of which were retrospective. Aboubakr Elnashar
  • 21. Results The majority (n=10) of these studies did not detect a statistically significant association between P elevation& the probability of pregnancy. Metaanalysis was performed only for the studies (n=5) that provided data on clinical pregnancy per patient reaching hCG administration for final oocyte maturation. No statistically significant association between P elevation& the probability of clinical pregnancy. Aboubakr Elnashar
  • 22. Conclusion: Best available evidence does not support an association between P elevation on the day of hCG administration& the probability of clinical pregnancy in women undergoing ovarian stimulation with GnRH analogues& Gnt for IVF. Aboubakr Elnashar
  • 23. PREVENTION I. Low-dose hCG alone in the late COH stages: (Filicori et al, 2005) rFSH/hMG followed by low-dose hCG (200 IU/d) alone : Reduced rFSH/hMG consumption ICSI outcome was comparable to traditional COH regimens Stimulated follicle growth and maturation independent of FSH administration Reduced number of small preovulatory follicles More estrogenic intrafollicular environment. No PL Aboubakr Elnashar
  • 24. II. Flexible antagonist protocol (Lainas et al, 2005) GnRH antagonist was initiated according to at least one of the following (i) at least one follicle >14 mm (ii)E2 >600 pg/ml (iii)LH levels >10 IU/l.  Antagonist initiation earlier than on stimulation D6  Higher PR  Prevention of premature LH surges  Absence of PL (normal P levels on HCG day). Aboubakr Elnashar
  • 25. III. Mifepristone (Escudero et al, 2005) :long protocol with GnRHa Mifepristone: 40 mg daily, 50 mg progesterone were administered IM at the time of hCG administration {counteract residual antiprogestogenic activity of mifepristone}. Mifepristone is effective for the prevention of premature LH surges and/or PL Aboubakr Elnashar
  • 26. VI. hCG injection when serum P >1.0 ng/mL ("rescued" subtle P rise). (Harada et al, 1996) •Serum P was determined daily or/ 12 h from D7 until the administration of hCG. improves embryo quality implantation rate was significantly higher Aboubakr Elnashar
  • 27. V. Aspiration of a single leading follicle (Barash et al, 1990) •Single leading follicle developed, whereas the other follicles were 6 mm smaller Efficient method to avoid premature LH surge enabling other follicles to develop up to the preovulatory stage. Aboubakr Elnashar
  • 28. SUMMARY PL •Subtle rise of P on the day of hCG administration (0.8 to 2 ng/Ml) •There is a marked variation in the incidence (13% to 71%), due to discrepancies in Definition Population characteristics Treatment protocols. Aboubakr Elnashar
  • 29. •Several hypotheses: Elevation of follicular LH levels Serum accumulation of HCG from HMG Increased LH receptor sensitivity of the granulosa cells to FSH Poor ovarian response with increased LH sensitivity Aboubakr Elnashar
  • 30. •Impact on IVF outcome is controversial. A recent systematic review& meta-analysis affirmed that no effect •For prevention: Use of Low-dose hCG alone in the late COH stages Flexible antagonist protocol Use of mifepristone hCG administration when the levels of P>1.0 ng/mL. Aspiration of a single leading follicle Aboubakr Elnashar
  • 31. RECOMMENDATION A well-designed prospective studies are required to answer the question: What is the role of P elevation on IVF outcome? Aboubakr Elnashar